[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368242-105":59,"doc-detail-368242-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genome-wide-crispr-screening-identifies-phf8-as-an-effective-therapeutic-target-for-kras-or-braf-mutant-colorectal-cancers","Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers","","Colorectal cancer (CRC) frequently harbors KRAS and BRAF mutations, which drive tumorigenesis and limit treatment responses, making effective therapeutic targets urgently needed. Using a CRISPR-Cas9 lentiviral knockout screen, the study evaluates immunotherapy suppressors and links PHF8 expression to immune indicators. In vitro and in vivo experiments show PHF8 promotes oncogenic phenotypes and immune escape by regulating PD-L1 and key oncogenic genes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genome-wide-crispr-screening-identifies-phf8-as-an-effective-therapeutic-target-for-kras-or-braf-mutant-colorectal-cancers/368242/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genome-wide-crispr-screening-identifies-phf8-as-an-effective-therapeutic-target-for-kras-or-braf-mutant-colorectal-cancers/368242.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PHF8 play in KRAS- or BRAF-mutant colorectal cancer?","Question",{"text":112,"@type":113},"PHF8 is identified as a negative regulator of anti-PD1 therapy efficacy and as highly expressed in CRCs. It promotes oncogenic behavior in KRAS- or BRAF-mutant CRC cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was PHF8 evaluated in the study?",{"text":117,"@type":113},"A genome-wide CRISPR-Cas9 lentiviral knockout library screened suppressors of anti-PD1 immunotherapy. The work also used bioinformatics and in vitro/in vivo experiments, including qRT-PCR, western blot, IHC, and ChIP-qPCR.",{"name":119,"@type":110,"acceptedAnswer":120},"Through which mechanism does PHF8 influence immune escape and tumor progression?",{"text":121,"@type":113},"PHF8 up-regulates PD-L1, KRAS, BRAF, and c-Myc by increasing activating histone marks (H3K4me3, H3K27ac) and decreasing a repression mark (H3K9me2) at promoter regions. It also participates in a positive feedback loop via the c-Myc/miR-22-3p axis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368242,1790218140,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Liu et al. Journal of Experimental & Clinical Cancer Research (2025) 44:70 [https://doi.org/10.1186/s13046-025-03338-2](https://doi.org/10.1186/s13046-025-03338-2)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nGenome-wide CRISPR screening identifies  PHF8 as an effective therapeutic target for KRAS-or BRAF-mutant colorectal cancers  \nZhao Liu 1,2†, Yiqi Li3†, Simeng Wang 1, Yubo Wang 1, Mengjun Sui 1, Jiaxin Liu4, Pu Chen 1, Jianling Wang 1, Yuchen Zhang5, Chengxue Dang2* and Peng Hou 1*  \nAbstract  \nBackground Mutations in KRAS and BRAF genes are prevalent in colorectal cancer (CRC), which strikingly promote tumorigenesis and lead to poor response to a variety of treatments including immunotherapy by activating the MAPK/ERK pathway. Thus, there is an urgent need to discover effective therapeutic targets and strategies.  \nMethods CRISPR-Cas9 lentiviral knockout library was used to screen the suppressors of anti-PD1 immunotherapy. Bioinformatic analysis was used to analyze the correlation between PHF8 expression and immune indicators in CRC. In vitro and in vivo experiments were utilized to determine the effects of PHF8 on the immune indexes and malignant phenotypes of CRC cells. qRT-PCR, western blotting, immunohistochemical (IHC) staining, and chromatin immunoprecipitation (ChIP)-qPCR assays were used to determine the regulatory effects of PHF8 on PD-L1, KRAS, BRAF, and c-Myc and the regulatory effect c-Myc/miR-22-3p signaling axis on PHF8 expression in CRC cells.  \nResults This study identified histone lysine demethylase PHF8 as a negative regulator for the efficacy of anti-PD1 therapy and found that it was highly expressed in CRCs and strongly associated with poor patient survival. Functional studies showed that PHF8 played an oncogenic role in KRAS-or BRAF-mutant CRC cells, but not in wild-type ones. Mechanistically, PHF8 up-regulated the expression of PD-L1, KRAS, BRAF, and c-Myc by increasing the levels of transcriptional activation marks H3K4me3 and H3K27ac and decreasing the levels of transcriptional repression mark H3K9me2 within their promoter regions, promoting immune escape and tumor progression. Besides, our data also demonstrated that PHF8 was up-regulated by the c-Myc/miR-22-3p signaling axis to form a positive feedback loop. Targeting PHF8 substantially improved the efficacy of anti-PD1 therapy and inhibited the malignant phenotypes of KRAS-or BRAF-mutant CRC cells.  \nConclusion Our data demonstrate that PHF8 may be an effective therapeutic target for KRAS-or BRAF-mutant CRCs. Keywords Colorectal cancer, PHF8, Immune escape, KRAS mutations, BRAF mutations  \n†Zhao Liu and Yiqi Li contributed equally to this work.  \n*Correspondence:  \nChengxue Dang [dangchengxue@mail.xjtu.edu.cn](dangchengxue@mail.xjtu.edu.cn)[ ](dangchengxue@mail.xjtu.edu.cn)Peng Hou  \n[phou@xjtu.edu.cn](phou@xjtu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/","cbCaiis14bB9e0fK","https://ap.wps.com/l/cbCaiis14bB9e0fK","pdf",4270563,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What role does PHF8 play in KRAS- or BRAF-mutant colorectal cancer?\",\"answer\":\"PHF8 is identified as a negative regulator of anti-PD1 therapy efficacy and as highly expressed in CRCs. It promotes oncogenic behavior in KRAS- or BRAF-mutant CRC cells.\"},{\"question\":\"How was PHF8 evaluated in the study?\",\"answer\":\"A genome-wide CRISPR-Cas9 lentiviral knockout library screened suppressors of anti-PD1 immunotherapy. The work also used bioinformatics and in vitro/in vivo experiments, including qRT-PCR, western blot, IHC, and ChIP-qPCR.\"},{\"question\":\"Through which mechanism does PHF8 influence immune escape and tumor progression?\",\"answer\":\"PHF8 up-regulates PD-L1, KRAS, BRAF, and c-Myc by increasing activating histone marks (H3K4me3, H3K27ac) and decreasing a repression mark (H3K9me2) at promoter regions. It also participates in a positive feedback loop via the c-Myc/miR-22-3p axis.\"}]","Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers | PDF",1790175844,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f5ffa3603f5c6c9b61ed52bb70606e7.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1774b7ba678ad32a8fdc6783d2a20f2.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77c4bd38cd97ce16cc3d7140788c208c.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ef7d5a7e812ffc0aa66204d0bba10ad.webp",980,1306]